Hematologic Oncology Update

Latest Episodes:

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens Nov 06, 2026

Show notes

Featuring an interview with Dr Matthew Lunning, including the following topics:

Bispecific antibody/antibody-drug conjugate combinations (0:00)
A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07)

CME information and select publications

Diffuse Large B-Cell Lymphoma — A Grand Rounds Program Nov 04, 2026

Show notes

Featuring a presentation by Dr Matthew Matasar, including the following topics:

Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)
Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)
Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)
Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)
Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)
Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)
Discussion of Questions from the Community (50:20)

CME information and select publications

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis Nov 02, 2026

Show notes

Featuring an interview with Dr Matthew Lunning, including the following topics:

A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)
CNS prophylaxis in non-Hodgkin lymphoma (7:58)

CME information and select publications

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6 Oct 28, 2026

Show notes

Featuring perspectives from Dr Lindsey Roeker, including the following topics:

Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)
Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)
Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)

CME information and select publications

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5 Oct 28, 2026

Show notes

Featuring perspectives from Dr Lindsey Roeker, including the following topics:

Consensus Approach to optimizing front-line treatment (0:00)
Emerging role of sonrotoclax (8:39)
Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)
Evolving role of minimal residual disease assessment (19:16)

CME information and select publications

Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome Oct 21, 2026

Show notes

Featuring perspectives from Dr Spencer Bachow, Dr Bhavana (Tina) Bhatnagar, Dr Jennifer Crombie, Dr Manali Kamdar and Ms Alexandra Lynch, co-moderated by Dr Bachow and Dr Bhatnagar, including the following topics:

Introduction and Overview of Bispecific Antibodies in the Clinic (0:00)
Current and Future Role of Bispecific Antibodies in Non-Hodgkin Lymphoma — Dr Kamdar (15:58)
Case: A man in his early 60s with diffuse large B-cell lymphoma (DLBCL) receives glofitamab (42:40)
Case: A woman in her early 80s with follicular lymphoma (FL) receives mosunetuzumab (51:50)
Mitigation and Management of Cytokine Release Syndrome (CRS) and Other Toxicities Associated with Bispecific Antibodies — Dr Crombie (1:00:39)
Case: A woman in her early 80s with DLBCL receives glofitamab (1:18:50)
Case: A woman in her early 70s with FL receives epcoritamab (1:26:38)
Outpatient CRS Management in B-Cell Lymphomas — Ms Lynch (1:29:28)
Case: A woman in her late 40s with FL receives epcoritamab (1:38:33)
Case: A man in his early 70s with mantle cell lymphoma receives mosunetuzumab (1:46:26)

CME information and select publications

Chronic Lymphocytic Leukemia — Microlearning Activity 2 Oct 16, 2026

Show notes

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Phase III BRUIN CLL-322 trial of fixed-duration pirtobrutinib in combination with venetoclax and rituximab for previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (0:00)
Role of allogeneic hematopoietic cell transplantation and chimeric antigen receptor T-cell therapy for relapsed/refractory (R/R) CLL (10:42)
Fixed-duration venetoclax in combination with epcoritamab for R/R CLL/SLL; management of Richter’s transformation (15:50)
Novel Bruton tyrosine kinase degraders bexobrutideg (NX-5948) and tacabrutideg (BGB-16673) (22:51)

CME information and select publications

Chronic Lymphocytic Leukemia — Microlearning Activity 1 Oct 15, 2026

Show notes

Featuring perspectives from Dr Catherine C Coombs, including the following topics:

Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00)
Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10)
Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05)
Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22)

CME information and select publications

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting Oct 12, 2026

Show notes

Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:

Introduction (0:00)
New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)
Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)
Potential Role of Cereblon E3 Ligase Modulators and Other Promising Novel Agents and Strategies for R/R MM — Prof Dimopoulos (41:12)

CME information and select publications

Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management Oct 08, 2026

Show notes

Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:

Introduction (0:00)
Minimal Residual Disease Assays in Community-Based Practice (1:24)
New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)
Richter Transformation (30:43)
Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Hematologic Oncology Update

Related Podcasts

Links

Stay Connected